Skip to main content
Signal8

COLLPLANT BIOTECHNOLOGIES REPORTS 2026 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

$CLGNPress releaseMay 29, 2026, 7:00 AM ETRead the release

CollPlant Biotechnologies reported Q1 2026 GAAP revenue of $73,000, a 96% decline year-over-year, driven by the absence of a $2.0 million one-time milestone payment received in the prior year. The company posted a GAAP net loss of $3.1 million ($0.23 per share), widening from a $1.5 million loss in Q1 2025, despite reducing operating expenses by approximately 18% through a 50% headcount reduction.

Key figures

Revenue
73000
Revenue Yoy
-96.4%
Headcount reduction
50%
Cash and equivalents
4262000

AI analysis

Red flags4 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.